maftivimab
E468964
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
Statements (43)
| Predicate | Object |
|---|---|
| instanceOf |
Ebola virus treatment
ⓘ
monoclonal antibody ⓘ therapeutic antibody ⓘ |
| actsSynergisticallyWith |
atoltivimab
NERFINISHED
ⓘ
odesivimab NERFINISHED ⓘ |
| approvalYear | 2020 ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| belongsToDrugClass |
antiviral monoclonal antibodies
ⓘ
immunoglobulins ⓘ |
| componentOf | fixed-dose combination with atoltivimab and odesivimab ⓘ |
| developedBy | Regeneron Pharmaceuticals NERFINISHED ⓘ |
| hasATCCode | J06BD53 ⓘ |
| hasCASNumber | 2098781-36-4 ⓘ |
| hasINN | maftivimab NERFINISHED ⓘ |
| hasLegalStatus | prescription-only medicine ⓘ |
| hasMolecularTarget |
Ebola virus glycoprotein
NERFINISHED
ⓘ
Zaire ebolavirus glycoprotein ⓘ |
| hasPharmacologicalEffect |
improvement of survival in Ebola virus disease patients
ⓘ
reduction of Ebola virus load ⓘ |
| hasUNII | 0YH6ZK4Z4E ⓘ |
| indication |
treatment of infection caused by Zaire ebolavirus in adults
ⓘ
treatment of infection caused by Zaire ebolavirus in children ⓘ treatment of infection caused by Zaire ebolavirus in neonates born to infected mothers ⓘ |
| isHumanized | true ⓘ |
| isMarketedAs | Inmazeb (in combination with atoltivimab and odesivimab) NERFINISHED ⓘ |
| isNotIndicatedFor |
post-exposure prophylaxis of Ebola virus disease
ⓘ
pre-exposure prophylaxis of Ebola virus disease ⓘ |
| isUsedIn | hospital setting ⓘ |
| mechanismOfAction | binds to Ebola virus glycoprotein and neutralizes viral entry into host cells ⓘ |
| origin | recombinant DNA technology ⓘ |
| partOf |
Inmazeb
NERFINISHED
ⓘ
REGN-EB3 antibody cocktail NERFINISHED ⓘ |
| pregnancyCategory | insufficient human data ⓘ |
| regimen | single-dose intravenous infusion as part of fixed-dose combination ⓘ |
| risk |
hypersensitivity reactions
ⓘ
infusion-related reactions ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targetOrganism | Zaire ebolavirus NERFINISHED ⓘ |
| therapyType | passive immunotherapy ⓘ |
| usedFor |
treatment of Ebola virus disease
ⓘ
treatment of Zaire ebolavirus infection ⓘ |
| usedWith |
atoltivimab
ⓘ
odesivimab ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.